Literature DB >> 16937364

The isoform-specific functions of the c-Jun N-terminal Kinases (JNKs): differences revealed by gene targeting.

Marie A Bogoyevitch1.   

Abstract

The c-Jun N-terminal kinases (JNKs) are members of the mitogen-activated protein kinase (MAPK) family. In mammalian genomes, three genes encode the JNK family. To evaluate JNK function, mice have been created with deletions in one or more of three Jnk genes. Initial studies on jnk1(-/-) or jnk2(-/-) mice have shown roles for these JNKs in the immune system whereas studies on jnk3(-/-) mice have highlighted roles for JNK3 in the nervous system. Further studies have highlighted the contributions of JNK1 and/or JNK2 to a range of biological and pathological processes. These include bone remodelling and joint disease, inflammatory and autoimmune diseases, obesity, diabetes, cardiovascular disease, liver disease and tumorigenesis in addition to effects in neurons. These results emphasise the differences in the roles played by JNK isoforms in vivo and suggest that the design of JNK inhibitors for subsequent therapeutic uses may benefit from selective inhibition of individual JNK isoforms. (c) 2006 Wiley periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16937364     DOI: 10.1002/bies.20458

Source DB:  PubMed          Journal:  Bioessays        ISSN: 0265-9247            Impact factor:   4.345


  69 in total

1.  Distinct roles of c-Jun N-terminal kinase isoforms in neurite initiation and elongation during axonal regeneration.

Authors:  Monia Barnat; Hervé Enslen; Friedrich Propst; Roger J Davis; Sylvia Soares; Fatiha Nothias
Journal:  J Neurosci       Date:  2010-06-09       Impact factor: 6.167

Review 2.  Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale.

Authors:  Beth A Rose; Thomas Force; Yibin Wang
Journal:  Physiol Rev       Date:  2010-10       Impact factor: 37.312

3.  Measuring the constitutive activation of c-Jun N-terminal kinase isoforms.

Authors:  Ryan T Nitta; Shawn S Badal; Albert J Wong
Journal:  Methods Enzymol       Date:  2010       Impact factor: 1.600

Review 4.  Uses for JNK: the many and varied substrates of the c-Jun N-terminal kinases.

Authors:  Marie A Bogoyevitch; Bostjan Kobe
Journal:  Microbiol Mol Biol Rev       Date:  2006-12       Impact factor: 11.056

5.  The role of the c-Jun N-terminal kinase 2-α-isoform in non-small cell lung carcinoma tumorigenesis.

Authors:  R T Nitta; C A Del Vecchio; A H Chu; S S Mitra; A K Godwin; A J Wong
Journal:  Oncogene       Date:  2010-09-27       Impact factor: 9.867

6.  Requirements for PKC-augmented JNK activation by MKK4/7.

Authors:  Pablo Lopez-Bergami; Ze'ev Ronai
Journal:  Int J Biochem Cell Biol       Date:  2007-12-03       Impact factor: 5.085

7.  The c-Jun NH2-terminal kinase 2 plays a dominant role in human epidermal neoplasia.

Authors:  Hengning Ke; Rebecca Harris; Jonathan L Coloff; Jane Y Jin; Benjamin Leshin; Paula Miliani de Marval; Shiying Tao; Jeffrey C Rathmell; Russell P Hall; Jennifer Y Zhang
Journal:  Cancer Res       Date:  2010-03-30       Impact factor: 12.701

8.  Improved insulin sensitivity with calorie restriction does not require reduced JNK1/2, p38, or ERK1/2 phosphorylation in skeletal muscle of 9-month-old rats.

Authors:  Naveen Sharma; Abhijit D Bhat; Anketse D Kassa; Yuanyuan Xiao; Edward B Arias; Gregory D Cartee
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-10-19       Impact factor: 3.619

9.  Regulation of expression of matrix metalloproteinase-9 by JNK in Raw 264.7 cells: presence of inhibitory factor(s) suppressing MMP-9 induction in serum and conditioned media.

Authors:  Yun Song Lee; Huong Thi Lan Tran; Quang Van Ta
Journal:  Exp Mol Med       Date:  2009-04-30       Impact factor: 8.718

10.  c-Jun N-terminal kinase 1 is deleterious to the function and survival of murine pancreatic islets.

Authors:  J L Varona-Santos; A Pileggi; R D Molano; N Y Sanabria; A Ijaz; M Atsushi; H Ichii; R L Pastori; L Inverardi; C Ricordi; A Fornoni
Journal:  Diabetologia       Date:  2008-10-14       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.